Literature DB >> 31656359

Prevalence of additional primary malignancies detected incidentally on PET/CT.

Joseph C Lee1,2, Marcelo Santos Teles1.   

Abstract

Entities:  

Year:  2019        PMID: 31656359      PMCID: PMC6808612          DOI: 10.1590/0100-3984.2019.0097

Source DB:  PubMed          Journal:  Radiol Bras        ISSN: 0100-3984


× No keyword cloud information.
Dear Editor, We entirely agree with the conclusions of Tibana et al.([1]). Although false-positives can occur with 18F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT), the prevalence of true-positives cannot be underestimated. Additional primary malignancies may often be identified by this means and the likelihood of cure is much increased if such malignancies are treated promptly and aggressively. It was unclear what is the actual prevalence of malignancies discovered with PET/CT in this study. The prevalence of additional malignancies discovered with PET/CT was highlighted in the various systems for breast([2]), bowel([3]), prostate([4]) and thyroid([5]) lesions. For example, in a study of 1665 patients, 70 incidentally detected lesions in the colon were identified and eventually 10 were diagnosed with bowel carcinoma([3]). There were additional pre-malignant lesions identified and early treatment was warranted in this scenario. Thus, it was found the prevalence of malignant and pre-malignant findings in the PET population was about 1.3%. A similar series showed a lower number of carcinomas but more adenomas (which would, of course, be considered pre-malignant) in a slightly larger series([6]). Hence, the prevalence was similar (at 1.1%). Knowing the prevalence may give a better idea of the importance of the incidental findings. This would be very helpful for both managing the individual patient as well as for public health and population health purposes.
  6 in total

1.  Significance of incidental 18F-FDG accumulations in the gastrointestinal tract in PET/CT: correlation with endoscopic and histopathologic results.

Authors:  Ehab M Kamel; Miriam Thumshirn; Kaspar Truninger; Marc Schiesser; Michael Fried; Barbara Padberg; Didier Schneiter; Sandro J Stoeckli; Gustav K von Schulthess; Katrin D M Stumpe
Journal:  J Nucl Med       Date:  2004-11       Impact factor: 10.057

2.  Incidental thyroid lesions on FDG-PET/CT: a prevalence study and proposition of management.

Authors:  M Adas; G Adas; B Koc; F Ozulker
Journal:  Minerva Endocrinol       Date:  2015-09       Impact factor: 2.184

3.  Multicentric study on ¹⁸F-FDG-PET/CT breast incidental uptake in patients studied for non-breast malignant purposes.

Authors:  Francesco Bertagna; Laura Evangelista; Arnoldo Piccardo; Mattia Bertoli; Giovanni Bosio; Raffaele Giubbini; Emanuela Orlando; Giorgio Treglia
Journal:  Rev Esp Med Nucl Imagen Mol       Date:  2014-10-11       Impact factor: 1.359

4.  The segmental distribution and clinical significance of colorectal fluorodeoxyglucose uptake incidentally detected on PET-CT.

Authors:  Joseph C Lee; Gemma F Hartnett; Brett G M Hughes; Aravind S Ravi Kumar
Journal:  Nucl Med Commun       Date:  2009-05       Impact factor: 1.690

5.  Prevalence and risk of cancer of incidental uptake in prostate identified by fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography.

Authors:  Zhongyi Yang; Silong Hu; Jingyi Cheng; Junyan Xu; Wei Shi; Beiling Zhu; Yongping Zhang; Zhifeng Yao; Herong Pan; Yingjian Zhang
Journal:  Clin Imaging       Date:  2014-02-07       Impact factor: 1.605

6.  Detection of additional primary malignancies: the role of CT and PET/CT combined with multiple percutaneous biopsy.

Authors:  Tiago Kojun Tibana; Rômulo Florêncio Tristão Santos; Adalberto Arão Filho; Bernardo Bacelar; Leticia de Assis Martins; Rafael Oliveira de Souza; Edson Marchiori; Thiago Franchi Nunes
Journal:  Radiol Bras       Date:  2019 May-Jun
  6 in total
  1 in total

1.  Synchronous tumours detected during cancer patient staging: prevalence and patterns of occurrence in multidetector computed tomography.

Authors:  Antonio Corvino; Sergio Venanzio Setola; Fabio Sandomenico; Fabio Corvino; Orlando Catalano
Journal:  Pol J Radiol       Date:  2020-05-26
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.